Remove Gene Remove Packaging Remove Vaccine
article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These programmes will include therapies and vaccines in infectious disease and oncology areas. These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

RNA 147
article thumbnail

Injectable opportunities for CMOs despite internal capacity of big pharma sponsors

Pharmaceutical Technology

Even giant pharma companies with large internal production capabilities are leaning on outsourcing to meet market demand for huge numbers of injectables, including high-value biologics and Covid-19 vaccines, according to a GlobalData analysis. Why do large and mega-cap sponsors outsource?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What Are Biopharmaceuticals?

Pharma Packaging Solutions

Vaccines: Vaccines, many of which are grown in tissue cultures, use microorganisms to provide immunity for specific diseases, and are one of the most wide-spread types of biopharma products. As biopharma technology progresses, becoming both more prevalent and available, the need for high-quality biopharma packaging increases.

article thumbnail

What is the Difference Between Biologics and Biosimilars?

Pharma Packaging Solutions

There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. Covid-19, flu, coronavirus liquid vaccine vial bottle and syringe set in plastic package container preparing for injection on white background.

article thumbnail

Covid-19 Omicron boosters will reinvigorate injectables manufacturing

Pharmaceutical Technology

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.

article thumbnail

Biden Outlines ‘Bold’ National Vaccine Effort

The Pharma Data

16, 2021 — President-elect Joe Biden described an ambitious national vaccination plan on Friday that will deliver coronavirus vaccines to far more people and invoke a wartime law to boost vaccine production. Even if Biden invokes the Korean War-era Defense Production Act, it may take some time to ease vaccine shortages.